<DOC>
	<DOC>NCT02738333</DOC>
	<brief_summary>This study will evaluate the antiviral efficacy of therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) and the safety and tolerability of LDV/SOF FDC and sofosbuvir (SOF) + ribavirin (RBV) in participants with chronic genotype 2 HCV (hepatitis C virus) infection.</brief_summary>
	<brief_title>Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
	<criteria>Key Chronic genotype 2 HCVinfected males and nonpregnant/nonlactating females Aged 20 years or older Treatment naive or treatment experienced At least 20 subjects will have ChildPughA compensated cirrhosis. In Cohort 2, participants must be ineligible or intolerant of RBV. Key Previous exposure to an NS5A or NS5B inhibitor Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) Pregnant or nursing female or male with pregnant female partner Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>